MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$3,369,000
EPS
-$0.11
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenues
---0
Research and development
413,000 1,376,000 634,000 363,000
Selling, general and administrative
2,435,000 4,219,000 2,748,000 1,150,000
Loss from operations
-2,848,000 -5,595,000 -3,382,000 -1,513,000
Gain on settlement of vendor payable
-249,500* --
Other
--312,000* -156,000
Unrealized gain on short-term investments
---0
Interest income
67,000 17,000 36,000 38,000
Interest expense
63,000 31,750* --
Loss on initial recognition of greenshoe rights liability
-20,209,000* --
Gain on settlement of vendor payable
---0
Change in fair value of greenshoe rights liability
--2,853,250* --
Change in fair value of warrant liability
-11,000 3,000 -232,000 114,000
Total other income, net
15,000 -17,436,000 268,000 80,000
Net loss
-2,833,000 -23,031,000 -3,114,000 -1,433,000
Dividend on series l preferred stock
--80,000* --
Dividend on preferred stock
103,000 ---
Deemed dividend
433,000 -5,786,000* 144,000 85,000
Net loss attributable to common stockholders
-3,369,000 -28,897,000 -3,258,000 -1,518,000
Basic EPS
-0.11 -5.241 -0.83 -0.55
Diluted EPS
-0.11 -5.241 -0.83 -0.55
Basic Average Shares
30,283,031 5,513,255* 3,940,714 2,771,765
Diluted Average Shares
30,283,031 5,513,255* 3,940,714 2,771,765
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to common...-$3,369,000 Interest income$67,000 (109.38%↑ Y/Y)Change in fair value ofwarrant liability-$11,000 (91.27%↑ Y/Y)Net loss-$2,833,000 (-265.08%↓ Y/Y)Deemed dividend$433,000 Dividend on preferredstock$103,000 Total other income,net$15,000 (-98.70%↓ Y/Y)Interest expense$63,000 Loss from operations-$2,848,000 (-47.41%↓ Y/Y)Selling, general andadministrative$2,435,000 (192.32%↑ Y/Y)Research and development$413,000 (-62.42%↓ Y/Y)

GT Biopharma, Inc. (GTBP)

GT Biopharma, Inc. (GTBP)